Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240036/S006

OmniaSecure MRI SureScan Lead Model 3930M

Medtronic, Inc. · Decision date Apr 24, 2026

FDA DECISIONP240036/S006

What did the FDA approve?

FDA records P240036/S006 as a supplement to PMA P240036, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Apr 24, 2026.

FDA approval order statement

Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240036/S004.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Apr 24, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240036/S006
Regulatory pathway
PMA supplement
Product code
NVY
Decision code
APPR
Decision date
Apr 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Permanent defibrillator electrodes.

Product code
NVY
FDA device class
3

For the original device and its historical approval scope, see PMA P240036. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240036 · Original PMA

    OmniaSecure MRI SureScan Lead Model 3930M

  2. P240036/S002 · Related supplement

    OmniaSecure MRI SureScan Lead Model 3930M

  3. P240036/S003 · Related supplement

    OmniaSecure MRI SureScan Lead Model 3930M

  4. P240036/S004 · Related supplement

    OmniaSecure MRI SureScan Lead Model 3930M

  5. P240036/S006 received

    Application receipt date recorded by FDA.

  6. P240036/S005 · Related supplement

    OmniaSecure MRI SureScan Lead Model 3930M

  7. P240036/S006 · FDA decision

    Normal 180 Day Track No User Fee

  8. P240036/S007 · Related supplement

    OmniaSecure MRI SureScan Lead Model 3930M

Timeline entries are records held by MedtechLedger for P240036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240036

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalApr 22, 2025FDA
Medtronic, Inc.PMA supplementOct 29, 2025FDA
Medtronic, Inc.PMA supplementOct 30, 2025FDA
Medtronic, Inc.PMA supplementMar 9, 2026FDA
Medtronic, Inc.PMA supplementApr 24, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code NVY

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementAug 19, 2026FDA
Medtronic, Inc.PMA supplementJun 24, 2026FDA
Medtronic, Inc.PMA supplementApr 15, 2026FDA
Medtronic, Inc.PMA supplementMar 6, 2026FDA
Medtronic, Inc.PMA supplementFeb 13, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records